Panbela Therapeutics IPO year
What is the IPO year of Panbela Therapeutics?
The IPO year of Panbela Therapeutics Inc. is 2020
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with ipo year similar to Panbela Therapeutics
- Acusensus Ltd has IPO year of 2019
- Grayscale Ethereum Trust (ETH) has IPO year of 2019
- Powerwrap Ltd has IPO year of 2019
- Powerwrap has IPO year of 2019
- National Rural Utilities Cooper has IPO year of 2019
- Listed Funds Trust has IPO year of 2019
- Panbela Therapeutics has IPO year of 2020
- Globally Local Technologies has IPO year of 2021
- uniQure N.V has IPO year of 2021
- Trustpilot plc has IPO year of 2021
- IQVIA has IPO year of 2021
- ACTIA S.A has IPO year of 2021
- Remark has IPO year of 2021